Table 1.
Characteristics of 13 aHUS patients.
| Case | Age | Gender | TMA Involvement Organ | Treatment | Disease Activity |
|---|---|---|---|---|---|
| a1 | 39 | M | Kidney, brain, lung, heart | PE | Stable |
| a3/a5 | 81 | M | Kidney, heart | a3 before 1st PE a5 after PE |
Unstable |
| a4 | 66 | M | Kidney, brain, heart | PE + anti C5 | Stable |
| a7 | 36 | F | Kidney, heart, pancreas, eye | PE + anti C5 | Stable |
| a8 | 33 | F | Kidney, brain, lung, heart | PE | Unstable |
| a9 | 62 | F | Kidney, brain, heart | PE + anti C5 | Unstable |
| a10 | 39 | M | Kidney, brain, lung, heart, eye | PE + anti C5 | Stable |
| a11 | 30 | F | Kidney, brain, lung, heart, eye, bowel | PE + anti C5 | Stable |
| a12 | 42 | F | Kidney, brain, lung, heart, pancreas, liver, eye, skin | PE + anti C5 | Stable |
| a13 | 53 | M | Kidney, brain, heart | PE + anti C5 | Stable |
| a14 | 70 | M | Kidney, brain, heart | PE | Unstable |
| a16 | 62 | F | Kidney, heart | PE | Stable |
| a17 | 49 | F | Kidney, brain, lung, heart, pancreas, liver, eye | PE + anti C5 | Stable |
F, female; M, male; TMA, thrombotic microangiopathy; PE, plasma exchange; anti-C5, anti-complement therapy.